MedTrace Logo

Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design

NCT06369727 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2024-04-17

No results posted yet for this study

Summary

A Randomized, Controlled Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design To evaluate the sensitization potential

Conditions

  • Erythema

Interventions

DRUG

MOB015B

Topcal formulation

DRUG

MOB015B vehicle

Topcal formulation

DRUG

Negative irritant solution of 0.9% saline

Negative control

Sponsors & Collaborators

  • Moberg Pharma AB

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-15
Primary Completion
2018-02-15
Completion
2018-02-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06369727 on ClinicalTrials.gov